Table 15Strength of evidence for intermediate health outcomes comparing etanercept versus acitretin

OutcomeStudy design and numberRisk of biasConsistencyDirectnessPrecisionsStrength of Evidence
Plaque BSARCT (2)Medium risk of biasConsistentDirectNAInsufficient
Observational (0)------------
PASIRCT (3)Medium risk of biasConsistentDirectNAModerate
Observational (0)------------
PGARCT (1)High risk of biasNADirectNAInsufficient
Observational (0)------------
Patient assessment of diseaseRCT (1)High risk of biasNADirectNAInsufficient
Observational (0)------------
Individual symptoms-joint painRCT (1)High risk of biasNADirectNAInsufficient
Observational (0)------------
Individual symptoms-itchingRCT (1)High risk of biasNADirectNAInsufficient
Observational (0)------------

BSA=body surface area; NA=not applicable; PASI=Psoriasis Area Severity Index; PGA=Physician’s Global Assessment; RCT=randomized controlled trial

From: Appendix G, Strength of Evidence for Outcomes

Cover of Biologic and Nonbiologic Systemic Agents and Phototherapy for Treatment of Chronic Plaque Psoriasis
Biologic and Nonbiologic Systemic Agents and Phototherapy for Treatment of Chronic Plaque Psoriasis [Internet].
Comparative Effectiveness Reviews, No. 85.
Lee S, Coleman CI, Limone B, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.